866-997-4948(US-Canada Toll Free)

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Jul 2017

Category :

Pharmaceutical

No. of Pages : 119 Pages

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2017

Summary

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Toll-like receptor 4 is a protein encoded by the TLR4 gene. This receptor is mostly expressed in placenta, and in myelomonocytic subpopulation of the leukocytes. It is involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni2+. It responses are triggered by Ni2+ require non-conserved. In complex with TLR6 promotes sterile inflammation in monocytes in response to oxidized low-density lipoprotein (oxLDL).

Toll Like Receptor 4 (hToll or CD284 or TLR4) pipeline Target constitutes close to 39 molecules. Out of which approximately 33 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 10, 3, 16 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 6 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Gastrointestinal, Immunology, Respiratory, Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones, Dermatology, Ear Nose Throat Disorders, Mouth and Dental Disorders, Musculoskeletal Disorders, Ophthalmology and Other Diseases which include indications Pulmonary Inflammation, Breast Cancer, Inflammation, Inflammatory Bowel Disease, Liver Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Atherosclerosis, Autoimmune Hepatitis, Drug Addiction, Kidney Disease, Kidney Fibrosis, Rheumatoid Arthritis, Sepsis, Soft Tissue Sarcoma, Traumatic Brain Injury, Acne Vulgaris, Acute Ischemic Stroke, Acute Lung Injury, Alcohol Addiction, Amyotrophic Lateral Sclerosis, Asthma, Atopic Dermatitis, Autoimmune Disorders, Bacterial Sepsis, Burns, Cervical Cancer, Crohn's Disease (Regional Enteritis), Ebolavirus Infections (Ebola Hemorrhagic Fever), Endotoxemia, Epilepsy, Escherichia coli Infections, Follicular Lymphoma, Globoid Cell Leukodystrophy (Krabbe Disease), Hearing Disorders, Hepatitis B, Hepatitis C, Hepatocellular Carcinoma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Human Papillomavirus (HPV) Associated Cancer, Human Papillomavirus Infections, Ischemia Reperfusion Injury, Keratoconjunctivitis sicca (Dry Eye), Leishmaniasis (Kala-Azar), Listeriosis, Lung Cancer, Marburgvirus Infections (Marburg Hemorrhagic Fever), Melanoma, Merkel Cell Carcinoma, Metastatic Melanoma, Multiple Sclerosis, Necrotizing Enterocolitis, Neuropathic Pain, Non Alcoholic Fatty Liver Disease (NAFLD), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Non-Hodgkin Lymphoma, Opium Withdrawal Syndrome, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Peanut Allergy, Phlebovirus Infections, Post-Traumatic Stress Disorder (PTSD), Primary Progressive Multiple Sclerosis (PPMS), Prostate Cancer, Pseudomonas aeruginosa Infections, Recurrent Glioblastoma Multiforme (GBM), Rosacea, Secondary Progressive Multiple Sclerosis (SPMS), Septic Shock, Trauma, Wounds, Xerostomia and Zika Virus Infections.

The latest report Toll Like Receptor 4 - Pipeline Review, H2 2017, outlays comprehensive information on the Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 4 (hToll or CD284 or TLR4)
- The report reviews Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 4 (hToll or CD284 or TLR4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Toll Like Receptor 4 (hToll or CD284 or TLR4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Overview 7
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Development 8
Products under Development by Stage of Development 8
Products under Development by Therapy Area 9
Products under Development by Indication 10
Products under Development by Companies 15
Products under Development by Universities/Institutes 22
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Assessment 25
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Companies Involved in Therapeutics Development 31
AptaTargets SL 31
Batu Biologics Inc 31
Biomedica Management Corp 32
Eisai Co Ltd 32
eTheRNA Immunotherapies NV 33
EyeGene Inc 33
Formune SL 34
GlaxoSmithKline Plc 34
Harbor Therapeutics Inc 35
Immune Design Corp 35
Immunovo BV 36
Kyorin Pharmaceutical Co Ltd 36
NovImmune SA 37
Sanofi 37
TaiwanJ Pharmaceuticals Co Ltd 38
Vascular Biogenics Ltd 39
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Drug Profiles 40
ApTOLL - Drug Profile 40
AyuV-25 - Drug Profile 41
Biologic to Agonize TLR4 for Drug Addiction - Drug Profile 42
C-34 - Drug Profile 43
CIA-05 - Drug Profile 44
CMB-305+G-100 - Drug Profile 45
CRX-526 - Drug Profile 46
DMT-210 - Drug Profile 47
Drugs to Agonize TLR4 for Oncology - Drug Profile 49
ECF-843 - Drug Profile 50
ECI-006 - Drug Profile 52
EDA-HPVE7 - Drug Profile 53
eritoran tetrasodium - Drug Profile 54
G-100 - Drug Profile 56
Glyco-23 - Drug Profile 60
GSK-1795091 - Drug Profile 61
HE-3286 - Drug Profile 62
hp-91 - Drug Profile 64
ibudilast - Drug Profile 65
ISAS-01 - Drug Profile 75
JKB-117 - Drug Profile 76
JKB-119 - Drug Profile 77
JKB-121 - Drug Profile 78
naltrexone hydrochloride - Drug Profile 79
NI-0101 - Drug Profile 81
P-13 - Drug Profile 83
P-16 - Drug Profile 84
P-7 - Drug Profile 85
P-MAPA - Drug Profile 86
PEPA-10 - Drug Profile 88
rabeximodum - Drug Profile 89
SAR-439794 - Drug Profile 90
Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 91
Small Molecules to Antagonize TLR2 and TLR4 for Immunology and Inflammation - Drug Profile 92
Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis - Drug Profile 93
Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease - Drug Profile 94
TWJ-201 - Drug Profile 95
VB-201 - Drug Profile 96
VB-703 - Drug Profile 99
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Dormant Products 100
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Discontinued Products 103
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Product Development Milestones 104
Featured News & Press Releases 104
Appendix 115
Methodology 115
Coverage 115
Secondary Research 115
Primary Research 115
Expert Panel Validation 115
Contact Us 115
Disclaimer 116

List of Tables
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indications, H2 2017
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1)
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by AptaTargets SL, H2 2017
Pipeline by Batu Biologics Inc, H2 2017
Pipeline by Biomedica Management Corp, H2 2017
Pipeline by Eisai Co Ltd, H2 2017
Pipeline by eTheRNA Immunotherapies NV, H2 2017
Pipeline by EyeGene Inc, H2 2017
Pipeline by Formune SL, H2 2017
Pipeline by GlaxoSmithKline Plc, H2 2017
Pipeline by Harbor Therapeutics Inc, H2 2017
Pipeline by Immune Design Corp, H2 2017
Pipeline by Immunovo BV, H2 2017
Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017
Pipeline by NovImmune SA, H2 2017
Pipeline by Sanofi, H2 2017
Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2017
Pipeline by Vascular Biogenics Ltd, H2 2017
Dormant Products, H2 2017
Dormant Products, H2 2017 (Contd..1), H2 2017
Dormant Products, H2 2017 (Contd..2), H2 2017
Discontinued Products, H2 2017

List of Figures
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *